Dopaminergic dysbalance in distinct basal ganglia neurocircuits: Implications for the pathophysiology of parkinson's disease, schizophrenia and attention deficit hyperactivity disorder

Neurotoxicity Research

Volumn 10, Issue 3-4, 2006, Pages 167-179

  Mehler Wex, C ^a   Riederer, Peter ^a   Gerlach, M ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Dyskinesia; Extrapyramidal motor symptoms; Limbic loop; Motor loop; Parkinsonism psychosis; Sleep disturbances

Indexed keywords

DOPAMINE; NEUROLEPTIC AGENT;

ATTENTION DEFICIT DISORDER; BASAL GANGLION; CYTOLOGY; HUMAN; METABOLISM; NERVE CELL NETWORK; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; PSYCHOSIS; REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BASAL GANGLIA; DOPAMINE; HUMANS; NERVE NET; PARKINSON DISEASE; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 33947508638     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033354     Document Type: Article

References (82)

1. Aarsland D, C Ballard, PJ Larsen and E McKeith (2001) A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int. J. Geriatr. Psychiatry 16, 528-536.
2. Alexander GE and MD Crutcher (1990) Functional architecture of basal ganglia circuits: Neural substrates of parallel processing. Trends Neurosci. 13, 266-271.
3. Alexander GE, MR DeLong and PL Strick (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Ann. Rev. Neurobiol. 9, 357-381.
4. Arnulf I, AM Bonnet, P Damier, BP Bejjani, D Seilhean, JP Derenne and Y Agid (2000) Hallucinations, REM sleep and Parkinson's disease. Neurology 55, 281-288.
5. Arnulf I, E Konofal, M Merino-Andreu, JL Houeto, V Mesnage, ML Welter, L Lacomblez, JL Golmard, JP Derenne and Y Agid (2002) Parkinson's disease and sleepiness. An integral part of PD. Neurology 58, 1019-1024.
6. Asarnow RF, KH Nuechterlein, KL Subotnik, DL Fogelson, RD Torquato, DL Payne, J Asamen, J Mintz and D Guthrie (2002) Neurocognitive impairments in nonpsychotic parents of children with schizophrenia and attention-deficit/hyperactivity disorder: The University of California, Los Angeles, Family Study. Arch. Gen. Psychiatry 59, 1053-1060.
7. Badura F, GE Trott, C Mehler, P Scheuerpflug, E Hofmann, M Warmuth-Metz, M Nadjmi, L Solymosi and A Warnke (2001) A study of cranial computer tomograms in very early and early onset schizophrenia. J. Neural Transm. 108, 1335-1344.
8. Barnes J, L Boubert, J Harris, A Lee and AS David (2003) Reality monitoring and visual hallucinations in Parkinson's disease. Neurpsychologia 41, 565-574.
9. Bergman H, T Wichman and MR DeLong (1990) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249, 1436-1438.
10. Bernheimer H, W Birkmayer, O Hornykiewicz, K Jellinger and F Seitelberger (1973) Brain dopamine and the syndromes of Parkinson and Huntington: Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20, 415-445.
11. Biederman J and SV Faraone (2005) Attention-deficit hyperactivity disorder. Lancet 366, 237-248.
12. Boks MPM, PF Liddle, JGM Burgerrhof, R Knegtering and RJ van den Bosch (2004) Neurological soft signs discriminating mood disorders from first episode schizophrenia. Acta Psychiatr. Scand. 110, 29-35.
13. Cadet JL and JB Lohr (1989) Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E. Ann. NYAcad. Sci. 570, 176-185.
14. Carlsson A (1977) Does dopamine plays a role in schizophrenia? Psychol. Med. 7, 583-597.
15. Carlsson ML (2000) On the role of cortical glutamate in obsessive-compulsive disorder and attention-deficit hyperactivity disorder, two phenomenologically antithetical conditions. Acta Psychiatr. Scand. 102, 401-413.
16. Carlsson A (2006) The neurochemical circuitry of schizophrenia. Pharmacopsychiatry 39 [Suppl. 1], S10-S14.
17. Carlsson M and A Carlsson (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13, 272-276.
18. Casey DE (2004) Pathophysiology of antipsychotic drug-induced movement disorders. J. Clin. Psychiatry [Suppl. 9] 65, 25-28.
19. Cools R, E Stefanova, RA Barker, TW Robbins and AM Owen (2002) Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain 125, 584-594.
20. Cortese L, MP Caligiuri, AK Malla, R Manchanda, J Takhar and R Haricharan (2005) Relationship of neuromotor disturbances to psychosis symptoms in first-episode neurolepticnaïve schizophrenia patients. Schizophr. Res. 75, 65-75.
21. DeLong MR (1990) Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 13, 281-285.
22. De Rijk MC, C Tzourio, MMB Breteler, JF Dartigues, L Amaducci, S Lopez-Pousa, JM Manubens-Bertran, A Alperovitchand WA Rocca (1997) Prevalence of parkinsonism and Parkinson's disease in Europe. The EUROPARKINSON collaborative study. J. Neurol. Neurosurg. Psychiatry 63, 10-15.
23. Decker MJ, G Keating, GE Hue, AA Freeman and DB Rye (2002) Mesolimbic dopamine's modulation of REM sleep. J. Sleep Res. [Suppl. 1] 11, 51-52.
24. Eisensehr I, R Linke, S Noachtar, J Schwarz, FJ Gildehaus and K Tatsch (2000) Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behavior disorder. Comparison with Parkinson's disease and controls. Brain 123, 1155-1160.
25. Elman I, M Sigler, J Kronenberg, JP Lindenmayer, A Doron, S Mendlovic and B Gaoni (1998) Characteristics of patients with schizophrenia successive to childhood attention deficit hyperactivity disorder. Isr. J. Psychiatry Relat. Sci. 35, 280-286.
26. Faraone SV and J Biederman (1998) Neurobiology of attention-deficit hyperactivity disorder. Biol. Psychiatry 44, 951-958.
27. Farmer AE and P McGuffin (1988) The pathogenesis and management of schizophrenia. Drugs 35, 177-185.
28. Foley P and P Riederer (2000) The motor circuit of the human basal ganglia reconsidered. J. Neural Transm. (Suppl.) 58, 97-110.
29. Francois C, D Grabli, K McCairn, C Jan, C Karachi, E-C Hirsch, J Feger and L Tremblay (2004) Behavioural disorders induced by external globus pallidus dysfunction in primates - II. Anatomical study. Brain 127, 2055-2070.
30. Gainetdinov RR and MC Caron (2001) Genetics of childhood disorders: XXIV. ADHD, part 8: Hyperdopaminergic mice as an animal model of ADHD. J. Am. Acad. Child. Adolesc. Psychiatry 40, 380-382.
31. Gerring J, K Brady, A Chen, C Quinn, E Herskovits, K Bandeen-Roche, MB Denckla and RN Bryan (2000) Neuroimaging variables related to development of secondary attention deficit hyperactivity disorder after closed injury in children and adolescents. Brain Inj. 14, 205-218.
32. Gottesman II and TD Gould (2003) The endophenotype concept in psychiatry: Etymology and strategic intentions. J. Am. Psychiatry 160, 636-645.
33. Graybiel AM (1990) Neurotransmitters and neuromodulators in the basal ganglia. Trends Neuosci. 13, 244-264.
34. Heiser P, S Friedel, A Dempfle, K Konrad, J Smidt, J Grabarkiewicz, B Herpertz-Dahlmann, H Remschmidt and J Hebebrand (2004) Molecular genetic aspects of attention-deficit/hyperactivity dsisorder. Neurosci. Biobehav. Rev. 28, 625-641.
35. Herzog J, J Reiff, P Krack, K Witt, B Schrader, D Müller and G Deuschl (2003) Manic episode with psychotic symptoms by subthalamic nucleus stimulation in a patient with Parkinson's disease. Mov. Disord. 18, 1382-1384.
36. Holroyd S, L Currie and GF Wooten (2001) Prospective study of hallucinations and delusions in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 70, 734-738.
37. Honer WG, LC Kopala and J Rabinowitz (2005) Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness. J. Psychopharmacol. 18, 277-285.
38. Ismail MS and IH Richard (2004) A reality test: How well do we understand psychosis in Parkinson's disease? J. Neuropsychiatry Clin. Neurosci. 16, 8-18.
39. Janno S, M Holi, K Tuisku and K Wahlbeck (2004) Prevalence of neuroleptic-induced disorders in chronic schizophrenia patients. Am. J. Psychiatry 161, 160-163.
40. Jellinger K (1989) Pathology of Parkinson's syndrome, In: Handbook of Experimental Pharmacology, Vol. 88 (Calne DB, Ed.) (Springer:BErlin, Heidelberg), pp 47-112.
41. Jenkins BG, R Sanchez-Pernaute, AL Brownell, IC Yin-Ching and O Isacson (2004) Mapping dopamine function in primates using pharmacologic magnetic resonance imaging. J. Neurosci. 24, 9553-9560.
42. Keshavan MS (1999) Development, disease and degeneration in schizophrenia: A unitary pathophysiological model. J. Psychiatr. Res. 33, 513-521.
43. Keshavan MS, M Sujata, A Mehra, DM Montrose and JA Sweeney (2003) Psychosis proneness and ADHD in young relatives of schizophrenia patients. Schizophr. Res. 59, 85-92.
44. Klawans HL and R Rubovitz (1972) An experimental model of tardive dyskinesia. J. Neural Transm. 33, 235-246.
45. Krause KH, SH Dresel, J Krause, HF Kung and K Tatsch (2001) Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: Effects of methylphenidate as measured by single photon emission computed tomography. Neurosci. Lett. 285, 107-110.
46. Kulisevsky J (2000) Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease. Drugs Aging 16, 365-379.
47. Laitinen LV (1995) Pallidotomy for Parkinson's disease. Neurosurg. Clin. N. Am. 6, 105-112.
48. Larisch R, W Sitte, C Antke, S Nikolaus, M Franz, W Tress and H-W Müller (2006). Striatal dopamine transporter density in drug naive patients with attention-deficit/hyperactivity disorder. Nucl. Med. Commun. 27, 267-270.
49. 2 receptor antagonism to glutamate NMDA facilitation. Clin. Ther. (Suppl. A) 27, S16-S24.
50. Lencer R, G Eismann, M Kasten, K Kabakci, V Geithe, J Grimm and CH Klein (2004) Family history of primary movement disorders as a predictor for neuroleptic-induced extrapyramidal symptoms. Brit. J. Psychiatry 185, 465-471.
51. Lencz T, CW Smith, A Auther, CU Correll and B Cornblatt (2004) Nonspecific and attenuated symptoms in patients at clinical high-risk for schizophrenia. Schizophr. Res. 68, 37-48.
52. Limousin P, P Pollak, A Benazzouz, D Hoffmann, JF Le Bas, E Broussolle, JE Perrett and AL Benabid (1995) Effect on parkinsonian signs and symptoms of bilateral subthalamic stimulation. Lancet 345, 91-95.
53. Lou HC, L Henriksen, P Bruhn, H Borner and JB Nielsen (1989). Striatal dysfunction in attention deficit and hyperkinetic disorder. Arch. Neurol. 46, 48-52.
54. Marsden CD (1990) Parkinson's disease. Lancet 335, 948-952.
55. Marsh L, JR Williams, M Rocco, S Grill, C Munro and TM Dawson (2004) Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology 63, 293-300.
56. Max JE, PT Fox, JL Lancaster, P Kochunov, K Mathews, FF Manes, BA Robertson, S Arndt, DA Robin and AE Lansing (2002) Putamen lesions and the development of attentiondeficit/hyperactivity symptomatology. J. Am. Acad. Child. Adolesc. Psychiatry 41(5), 563-571.
57. McCreadie RG, R Thara, TN Srinivasan and R Padmavathi (2003) Spontaneous dyskinesia in first-degree relatives of chronically ill, never-treated people with schizophrenia. Br. J. Psychiatry 183, 45-49.
58. Mehler C and A Warnke (2002) Structural brain abnormalities specific to childhood-onset schizophrenia identified by neuroimaging techniques. J. Neural Transm. 109, 219-234.
59. Narabayashi H, F Yokochi and Y Nakajima (1984) Levodopainduced dyskinesia and thalatomy. J. Neurol. Neurosurg. Psychiatry 47, 831-839.
60. Opler LA, DM Frank and PM Ramirez (2001) Psychostimulants in the treatment of adults with psychosis and attention deficit disorder. Ann. NY Acad. Sci. 297-301.
61. Pappert EJ, GG Goetz, FG Niederman, R Raman and S Leurgans (1999) Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Mov. Disord. 14, 117-121.
62. Pauletto G, E Belgrado, R Marinig and P Bergonzi (2004) Sleep disorders and extrapyramidal diseases: A historical review. Sleep Med. 5, 163-167.
63. Perry E, M Walker, J Grace and R Perry (1999) Acetylcholine in mind: A neurotransmitter correlate of consciousness? Trends Neurosci. 22, 273-280.
64. Pine DS, RG Klein, DC Lindy and RD Marshall (1994) Attention-deficit hyperactivity disorder and comorbid psychosis: A review and two clinical presentations. J. Clin. Psychiatry 54, 312-313.
65. Riederer P and S Wuketich (1976) Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis. J. Neural Transm. 38, 277-301.
66. Riederer P, KW Lange, J Kornhuber and W Danielczyk (1992) Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophrenia. Arzneimittelforsch. 42, 265-268.
67. Rubia K, S Overmeyer, E Taylor, M Brammer, SCR Williams, A Simmons and ET Bullmore (1999) Hypofrontality in attention deficit hyperactivity disorder during higher-order motor control: A study with functional MRI. Am. J. Psychiatry 156, 891-896.
68. Sanchez-Ramos JR, R Ortoll R and GW Paulson (1996) Visual hallucinations associated with Parkinson disease. Arch. Neurol. 53(12), 1265-1268.
69. Schafer D and W Greulich (2000) Effects of parkinsonian medications on sleep. J. Neurol. 247, 24-27.
70. Shafritz KM, KE Marchione, JC Gore, SE Shaywitz and BA Shaywitz (2004) The effects of methylphenidate on neural systems of attention in attention deficit hyperactivity disorder. Am. J. Psychiatry 161, 1990-1997.
71. Sian J, M Gerlach, MBH Youdim and P Riederer (1999) Parkinson's disease: A major hypokinetic basal ganglia disorder. J. Neural Transm. 106, 443-476.
72. Srinivasan TN, R Thara, R Padmavathi and RG McCreadie (2001) Relationship of extrapyramidal symptoms to age at onset and drug treatment in middle-aged and elderly schizophrenic patients. Schizophr. Res. 47, 69-75.
73. 3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol. Psychiatry 2, 139-145.
74. Sullivan RM and WG Brake (2003) What the rodent prefrontal cortex can teach us about attention-deficit/hyperactivity disorder: The critical role of early developmental events on prefrontal function. Behav. Brain Res. 146, 43-55.
75. Takakusaki K, K Saitoh, H Harada, T Okumura and T Sakamoto (2004) Evidence for a role of basal ganglia in the regulation of rapid eye movement sleep by electrical and chemical stimulation for the pedunculopontine tegemental nucleus and the substantia nigra pars reticulata in decerebrate rats. Neuroscience 124, 207-220.
76. Thanvi BR, SK Munshi, N Vijaykumar and TCN Lo (2003) Neuropsychiatric non-motor aspects of Parkinson's disease. Review. Postgrad. Med. J. 79, 561-565.
77. The Deep-Brain Stimulation for Parkinson's Disease Study Group (2001) Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N. Engl. J. Med. 345, 956-963.
78. Thompson PM, C Vidal, JN Giedd, P Gochman, J Blumenthal, R Nicolson, AW Toga and JL Rapoport (2001) Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early onset schizophrenia. Proc. Natl. Acad. Sci. USA 98, 11650-11655.
79. Vaidya CJ, G Austin, G Kirkorian, HW Ridlehuber, JE Desmond, GH Glover and JDE Gabrieli (1998) Selective effects of methylphenidate in attention deficit hyperactivity disorder: A functional magnetic resonance study. Proc. Natl. Acad. Sci. USA 95, 14494-14499.
80. Volkow ND, GJ Wang, JS Fowler, J Logan, M Gerasimov, L Maynard, YS Ding, S J Gatley, A Gifford and D Franceschi (2001) Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J. Neurosci. 2, U1-U5.
81. Wint DP, MS Okun and HH Fernandez (2004) Psychosis in Parkinson's diesease. Psychiatry Neurol. 17, 127-136.
82. Wonody I, HM Adami, SL Cassady, JD Sherr, MT Avila and GK Thaker (2004) Ethnicity and the course of tardive dyskinesia in outpatients presenting to the motor disorders clinic at the Maryland Psychiatric Research Center. J. Clin. Psychopharm-acol. 24, 592-598.